Description

Cagrisema

Cagrisema represents a breakthrough in multi-pathway metabolic signaling research. It is a high-purity synthetic combination of two long-acting peptides: Semaglutide (a GLP-1 receptor agonist) and Cagrilintide (a novel amylin receptor agonist). In the landscape of advanced endocrinology and obesity studies, Cagrisema is distinguished by its dual-target mechanism. While Semaglutide primarily enhances glucose-dependent insulin secretion and slows gastric emptying, Cagrilintide acts on the brain’s satiety centers to promote a significant reduction in caloric intake and improve metabolic efficiency. This synergy provides researchers with a robust experimental model to investigate extreme weight regulation, the reversal of insulin resistance, and the molecular pathways of systemic metabolic homeostasis beyond the capabilities of monotherapy.

Our Cagrisema is produced in an ISO 9001:2015 certified environment utilizing high-precision recombinant DNA and Solid-Phase Peptide Synthesis (SPPS) technologies. We achieve an ultra-high chemical purity of ≥99% for both components, verified by HPLC and Mass Spectrometry (MS). This rigorous production standard ensures the blend is free from impurities and structural variants, guaranteeing the high-fidelity data required for longitudinal studies into obesity and cardiovascular metabolic stability.

---

Research Applications & Mechanisms

Multi-Pathway Satiety & Appetite Regulation

Investigating the synergistic activation of GLP-1 and Amylin receptors in the hypothalamus to study the mechanisms of profound weight loss and energy balance.

Glucoregulatory Homeostasis

Researching the enhanced modulation of insulin and glucagon secretion to investigate the optimization of glycemic control in metabolic dysfunction models.

Gastric Emptying & Postprandial Signaling

Studying the influence of dual-agonism on gastrointestinal motility and its role in Investigating systemic nutrient absorption and metabolic rate.

Cardiovascualr & Adipose Tissue Research

Exploring the potential impact of Cagrisema on the reduction of visceral fat and its subsequent influence on cardiovascular inflammatory profiles.

---

Technical Specifications

Parameter	Laboratory Standard
Components	Semaglutide + Cagrilintide
Purity (HPLC)	≥99% (Pharmaceutical Grade)
Physical Appearance	Fine, Smooth & Flat Lyophilized Cake
Mechanism	Dual GLP-1R & AMYR Agonist
Concentrations	Available in 5mg, 10mg, 20mg vials
Solubility	Highly Soluble in Water (Aqueous) / Sterile Saline
Batch Control	HPLC, MS & Endotoxin Analysis Verified

---

Key Features & Quality Assurance

Advanced Co-Lyophilization Stability

Our proprietary vacuum-sealing process ensures the Cagrisema powder surface is perfectly smooth, flat, and delicate. This uniform “cake” structure ensures that both peptides remain stable and uniformly distributed for precise experimental dosing.

Verified Synergistic Ratio

Every batch is rigorously tested to ensure the precise stoichiometric ratio of Semaglutide and Cagrilintide, maintaining the intended synergistic potency required for high-stakes metabolic assays.

---

Reconstitution & Storage

Reconstitution Guide

• Preparation: Allow the vial to reach room temperature. Centrifuge for 30-60 seconds to ensure the Cagrisema cake is at the base.

• Solvent: Reconstitute with Sterile Water or Bacteriostatic Water.

• Technique: Gently introduce the diluent against the vial wall. DO NOT SHAKE; swirl gently until the solution is clear and transparent.

Storage Protocols

• Long-term: Store at -20°C (Maintains potency for up to 24 months).

• Short-term: Stable at 2–8°C for up to 3 months.

• Post-Reconstitution: Store at 2–8°C and utilize within 14-21 days for optimal results.

---

Shipping & Documentation

• Global Logistics: Shipped in discreet, temperature-controlled packaging to maintain the structural integrity of the Cagrisema blend.

• Verified Quality: A batch-specific COA and HPLC/MS reports are available for every order.

• Reshipment Policy: We provide a guaranteed reshipment policy for any lost or customs-intercepted orders (terms apply).

---

⚠️ Research Disclaimer

Product-Specific Safety Notice: This Cagrisema blend is strictly for laboratory research and analytical purposes. It is NOT intended for human or veterinary administration. All research must be conducted by qualified professionals.

---

Scientific Resources & References

• National Center for Biotechnology Information (NCBI): GLP-1 and Amylin Synergy in Obesity Research

• ScienceDirect (Elsevier): Peer-reviewed Research on Cagrilintide and Metabolic Regulation

---

🔍 Deep Dive Research

• [Technical Guide]: Optimizing Multi-Peptide Reconstitution for Reliable Research Data

• [Metabolic Study]: The New Frontier: Why Cagrisema is the Future of Obesity Research